Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy On Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study

被引：0
|
作者：
Strand, Vibeke [1 ]
Purcaru, Oana [2 ]
van Vollenhoven, Ronald F. [3 ]
Choy, Ernest [4 ]
Fleischmann, Roy [5 ]
机构：
[1] Stanford Univ, Portola Valley, CA USA
[2] UCB Pharma, Brussels, Belgium
[3] Karolinska Inst, Stockholm, Sweden
[4] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales
[5] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1318
引用
收藏
页码：S567 / S567
页数：1
相关论文
共 50 条
  • [21] Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study
    Strand, Vibeke
    Reaney, Matthew
    Mangan, Erin
    van Hoogstraten, Hubert
    Boklage, Susan
    Hu, Chih-Chi
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [22] Reduced Burden on Paid and Household Work Productivity with Stringent Thresholds of Disease Control: Further Results from Long-Term Certolizumab Pegol Treatment in Patients with Psoriatic Arthritis
    Tillett, William
    Coates, Laura
    Kiri, Sandeep
    Taieb, Vanessa
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3815 - 3817
  • [23] Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic arthritis
    Tillett, William
    Coates, Laura C.
    Kiri, Sandeep
    Taieb, Vanessa
    Willems, Damon
    Mease, Philip J.
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2022, 14
  • [24] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: FINAL RESULTS FROM THE BALANCE-EXTEND OPEN-LABEL EXTENSION STUDY
    Kivitz, A.
    Wells, A. F.
    Vargas, J. Ignacio
    Baraf, H. S. B.
    Rischmueller, M.
    Klaff, J.
    Khan, N.
    Li, Y.
    Carter, K.
    Friedman, A.
    Durez, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 620 - 621
  • [25] Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study
    Alan Kivitz
    Alvin F. Wells
    Juan I. Vargas
    Herbert S. B. Baraf
    Maureen Rischmueller
    Justin Klaff
    Nasser Khan
    Yihan Li
    Kyle Carter
    Alan Friedman
    Patrick Durez
    Rheumatology and Therapy, 2023, 10 : 901 - 915
  • [26] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: FINAL RESULTS FROM THE BALANCE-EXTEND OPEN-LABEL EXTENSION STUDY
    Kivitz, Alan
    Wells, Alvin F.
    Vargas, Juan I.
    Baraf, Herbert S. B.
    Rischmueller, Maureen
    Klaff, Justin
    Khan, Nasser
    Li, Yihan
    Carter, Kyle
    Friedman, Alan
    Durez, Patrick
    RHEUMATOLOGY, 2023, 62
  • [27] Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
    Yamanaka, Hisashi
    Tanaka, Yoshiya
    Takeuchi, Tsutomu
    Sugiyama, Naonobu
    Yuasa, Hirotoshi
    Toyoizumi, Shigeyuki
    Morishima, Yosuke
    Hirose, Tomohiro
    Zwillich, Samuel
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [28] Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study
    Kivitz, Alan
    Wells, Alvin F. F.
    Vargas, Juan I. I.
    Baraf, Herbert S. B.
    Rischmueller, Maureen
    Klaff, Justin
    Khan, Nasser
    Li, Yihan
    Carter, Kyle
    Friedman, Alan
    Durez, Patrick
    RHEUMATOLOGY AND THERAPY, 2023, 10 (04) : 901 - 915
  • [29] Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study
    Hisashi Yamanaka
    Yoshiya Tanaka
    Tsutomu Takeuchi
    Naonobu Sugiyama
    Hirotoshi Yuasa
    Shigeyuki Toyoizumi
    Yosuke Morishima
    Tomohiro Hirose
    Samuel Zwillich
    Arthritis Research & Therapy, 18
  • [30] LONG-TERM SAFETY AND EFFICACY OF OLOKIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS - RESULT OF AN OPEN-LABEL EXTENSION STUDY, CREDO4
    Feist, E.
    Nasonov, E.
    Luggen, M.
    Fatenejad, S.
    Grishin, S.
    Samsonov, M.
    Fleischmann, R. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 593 - 593
12345